TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02553824
Drug: Phentermine/Topiramate-First
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
Study: NCT02191332
Drug: Viramune
Normalized name: Viramune
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00577772
Drug: Xifaxan
Normalized name: XIFAXAN
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
Study: NCT02299440
Drug: 1st perfusion of ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
Study: NCT02337192
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02337192
Drug: Surfactant
Normalized name: Surfactant
DrugBank: Recombinant surfactant protein D (DB18438)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02299440
Drug: 2nd perfusion of ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
Study: NCT02337192
Drug: DMSO + water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02337192
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193921
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV, 25mg/m2, days 1, 8, 22
Study: NCT00193921
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg (flat dose) IV days 1, 8, 15
Study: NCT00193921
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/m2, IV, weekly
Study: NCT00039156
Drug: ortataxel
Normalized name: Ortataxel
DrugBank: Ortataxel (DB11669)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04268953
Drug: Tricaprilin
Normalized name: TRICAPRILIN
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricaprilin formulated as AC-SD-03 mixed in 300mL water
Study: NCT01145339
Drug: Lactase
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
Study: NCT02683239
Drug: Fasinumab
Normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive sub-cutaneous (SC) injections of fasinumab
Study: NCT03259152
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
Study: NCT04494269
Drug: Tegoprazan 50mg
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily
Study: NCT00202020
Drug: Cilostazol 200mg/day Oral
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01967771
Drug: DTG
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DTG will be supplied as 50 mg tablet to be administered orally
Study: NCT01967771
Drug: CBZ
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
Study: NCT04164368
Drug: Lenalidomide combined with R-CHOP
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
Study: NCT02104245
Drug: Ciprofloxacin dispersion for inhalation
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03214653
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
Study: NCT03214653
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
Study: NCT03400111
Drug: Panadol-extra
Normalized name: Panadol Extra
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
Study: NCT02410460
Drug: clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00873730
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50 mg twice a week (BIW) for 12 weeks
Study: NCT00873730
Drug: etanercept/placebo
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
Study: NCT02410460
Drug: glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02410460
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02410460
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02410460
Drug: marcaine
Normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02454348
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
Study: NCT02410460
Drug: scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02410460
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02410460
Drug: metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02410460
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02410460
Drug: famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02410460
Drug: desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02410460
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00223223
Drug: Levetiracetam, Keppra
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03413163
Drug: Ultrasound guided erector spinae plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
Study: NCT04202367
Drug: 1 mg.kg-1 bupivacaine 0.25%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
Study: NCT03221998
Drug: IV saline (NaCl 0.9 %)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
Study: NCT04202367
Drug: 1 mg.kg-1 bupivacaine 0.125%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
Study: NCT01867320
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
Study: NCT00652704
Drug: Doxycycline monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, 100 mg, fed
Study: NCT00652704
Drug: Monodox
Normalized name: Monodox
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, 100 mg, fed
Study: NCT00652704
Drug: Doxycycline Monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules, 100 mg, fasting
Study: NCT02318888
Drug: Icodextrin
Normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00357877
Drug: 10% w/v chlorhexidine acetate coating FDA IND #45466
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dental coating topically applied by dental professional supragingivally to the full dentition
Study: NCT02005575
Drug: Bupivacaine and Dexamethasone
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The standard of care is to use a regional block solution containing both decadron and bupivicaine.
Study: NCT00534872
Drug: SB-649868
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg
Study: NCT00767221
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg PL-56 once daily for six months
Study: NCT03231800
Drug: dasotraline
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dasotraline 2mg capsule once daily
Study: NCT00000173
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00504673
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00504673
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000173
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958046
Drug: Lansoprazole/Domperidone
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DUOLANS 30/30 mg SR tablet per oral, one tablet daily
Study: NCT00003187
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003187
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003187
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04253873
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
Study: NCT03803124
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet before renography
Study: NCT00951015
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: approved therapy for HIV-1 infection, used as an internal study control
Study: NCT05976373
Drug: Dupilumab (SAR231893)
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: injection solution subcutaneous
Study: NCT01538966
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01538966
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01538966
Drug: Lanreotide
Normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04644120
Drug: ABBV-47D11
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion.
Study: NCT04644120
Drug: ABBV-2B04
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervenous (IV) Infusion
Study: NCT04254081
Drug: Buprenorphine 0.15 MG
Normalized name: buprenorphine 0.15 MG
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.
Study: NCT04254081
Drug: Lidocaine 1% Injectable Solution
Normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.
Study: NCT02188654
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg/day retarded formulation of metformin
Study: NCT03556904
Drug: Hormone therapy or chemotherapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
Study: NCT00137969
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be supplied as a sterile liquid for IV administration.
Study: NCT00137969
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00137969
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01416389
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01416389
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT01416389
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT03711422
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40mg daily
Study: NCT03711422
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160mg for 3 days every 3 weeks
Study: NCT01365481
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
Study: NCT01365481
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
Study: NCT01365481
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
Study: NCT00538694
Drug: daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01404364
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,3mL intravitreal injection of Triamcinolone, single dose
Study: NCT01404364
Drug: Chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2,5mL Chlorpromazine retrobulbar injection, single dose
Study: NCT00472849
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 30 mg/m\^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
Study: NCT04019717
Drug: AT-527
Normalized name: AT-527
DrugBank: AT-527 (DB16451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
Study: NCT04019717
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhibitor of HCV nonstructural protein 5A (NS5A)
Study: NCT00004220
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004220
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00472849
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m\^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
Study: NCT00472849
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
Study: NCT02950935
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
Study: NCT00671996
Drug: Mangafodipir
Normalized name: Mangafodipir
DrugBank: Mangafodipir (DB06796)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy.
Study: NCT01482949
Drug: AGS-003
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Dendritic Cell Immunotherapy
Study: NCT01857323
Drug: Albuterol Spiromax®
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
Study: NCT00472849
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses).
Study: NCT00472849
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
Study: NCT01667094
Drug: Intermittent, short infusion Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime 1g q8/24
Study: NCT01667094
Drug: Continuous infusion Ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
Study: NCT01904110
Drug: Risedronate/Cholecalciferol combination(montly)
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a month
Study: NCT01667094
Drug: Intermittent, short infusion Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 1g q8/24, infusion over 30 minutes
Study: NCT01667094
Drug: Continuous infusion Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
Study: NCT01667094
Drug: Intermittent, short infusion Ticarcillin-clavulanate
DrugBank: Ticarcillin (DB01607)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticarcillin/clavulanate 3.1g q6/24
Study: NCT01667094
Drug: Continuous infusion Ticarcillin-clavulanate
DrugBank: Ticarcillin (DB01607)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24